Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer

We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Masakatsu, Otsuka, Toshimi, Hayashi, Ranji, Horita, Tomoe, Ota, Masafumi, Sakurai, Naoko, Takano, Hikaru, Hayashi, Tasuku, Kumagai, Motona, Yamada, Sohsuke, Arisawa, Tomiyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691038/
https://www.ncbi.nlm.nih.gov/pubmed/32669493
http://dx.doi.org/10.2169/internalmedicine.4699-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691038/
https://www.ncbi.nlm.nih.gov/pubmed/32669493
http://dx.doi.org/10.2169/internalmedicine.4699-20

Ejemplares similares